Innate Pharma SA (OTCMKTS:IPHYF) Short Interest Update

Innate Pharma SA (OTCMKTS:IPHYF) saw a significant growth in short interest during the month of August. As of August 14th, there was short interest totaling 16,627 shares, a growth of 341.0% from the July 30th total of 3,770 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average trading volume of 10 shares, the days-to-cover ratio is currently 1,662.7 days.

Innate Pharma Stock Performance

IPHYF stock remained flat at $1.65 during midday trading on Thursday. The business has a fifty day moving average price of $1.65 and a two-hundred day moving average price of $1.75. Innate Pharma has a 1-year low of $1.37 and a 1-year high of $2.25.

Innate Pharma Company Profile

Innate Pharma is a clinical-stage biotechnology company headquartered in Marseille, France, focused on harnessing the innate immune system to develop novel immunotherapies for oncology and inflammatory diseases. Founded in 1999, the company applies its expertise in natural killer (NK) cell and macrophage biology to design antibodies and other biologic agents that modulate immune checkpoints and enhance antitumor responses.

The company’s pipeline includes several lead programs such as monalizumab, an anti-NKG2A antibody designed to restore NK cell and CD8+ T cell activity, and lirilumab, which targets KIR receptors on NK cells to promote tumor cell killing.